每(mei)經AI快(kuai)訊， 今年以來(lai)，公(gong)(gong)(gong)募(mu)基金(jin)(jin)公(gong)(gong)(gong)司(si)參與上(shang)市公(gong)(gong)(gong)司(si)定(ding)(ding)增(zeng)項(xiang)目(mu)熱情高漲。Choice數據顯示，截至12月19日，58家公(gong)(gong)(gong)募(mu)基金(jin)(jin)公(gong)(gong)(gong)司(si)斥(chi)資逾1100億元參與定(ding)(ding)增(zeng)。從定(ding)(ding)增(zeng)結果來(lai)看，不少定(ding)(ding)增(zeng)項(xiang)目(mu)成為(wei)基金(jin)(jin)公(gong)(gong)(gong)司(si)掙錢的“法寶”，如華(hua)夏航(hang)空、開立醫(yi)療等(deng)定(ding)(ding)增(zeng)股票雖尚處限售期內，但已給基金(jin)(jin)公(gong)(gong)(gong)司(si)帶來(lai)可觀浮盈收益。與此(ci)同時，也有部分公(gong)(gong)(gong)募(mu)基金(jin)(jin)公(gong)(gong)(gong)司(si)在蔚藍鋰芯、邁克生物等(deng)定(ding)(ding)增(zeng)項(xiang)目(mu)上(shang)“栽跟頭”。（中國證券報）